Results 31 to 40 of about 4,816,902 (277)

Consideration of the novel psychoactive substances (‘legal highs’) [PDF]

, 2011
The Advisory Council on the Misuse of Drugs (ACMD) committed to providing the Government with advice on novel psychoactive substances (often colloquially termed „legal highs‟).

core   +6 more sources

The “Endless Trip” among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review

Frontiers in Psychiatry, 2017
Hallucinogen-persisting perception disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acute hallucinogen effects.
Laura Orsolini, Laura Orsolini, Laura Orsolini, Gabriele Duccio Papanti, Domenico De Berardis, Domenico De Berardis, Domenico De Berardis, Amira Guirguis, John Martin Corkery, Fabrizio Schifano   +9 more
doaj   +1 more source

Recent Changes in Drug Abuse Scenario The Novel Psychoactive Substances (NPS) Phenomenon [PDF]

, 2019
Over the last decade, the emergence of a vast range of new/novel/emerging psychoactive substances (NPS) has progressively changed drug market scenarios, which have shifted from the ‘street’ to a ‘virtual’/online environment. Several definitions of NPS
Giulia Stocchero, Susanna Vogliardi, Donata Favretto, Luca Menilli, Salvatore Scrivano, Giorgia Miolo, Massimo Montisci, Marianna Tucci   +7 more
core   +1 more source

Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database

Brain Sciences, 2020
Background: Clozapine is of high clinical relevance for the management of both treatment-resistant schizophrenia and psychotic disturbances with concurrent drug misuse.
Stefania Chiappini, Fabrizio Schifano, John Martin Corkery, Amira Guirguis   +3 more
doaj   +1 more source

The Novel Psychoactive Substances Epidemic: a Scientometric Perspective

Addiction Neuroscience, 2022
Abstract The unprecedented proliferation of novel psychoactive substances (NPS) in the illicit drug market has been a public health concern since their emergence in the 2000s. Their consumption can pose a severe health risks as their mechanism of action is poorly understood and their level of toxicity is high mainly due to the diffusion
Michelle Jin Yee Neoh, Alessandro Carollo, Mengyu Lim, Ornella Corazza, Aurora Coppola, Gianluca Esposito   +5 more
openaire   +3 more sources

The Psychonauts’ World of Cognitive Enhancers

Frontiers in Psychiatry, 2020
BackgroundThere is growing availability of novel psychoactive substances (NPS), including cognitive enhancers (CEs) which can be used in the treatment of certain mental health disorders.
Flavia Napoletano, Flavia Napoletano, Fabrizio Schifano, John Martin Corkery, Amira Guirguis, Amira Guirguis, Davide Arillotta, Davide Arillotta, Caroline Zangani, Caroline Zangani, Alessandro Vento, Alessandro Vento, Alessandro Vento   +12 more
doaj   +1 more source

Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset

Pharmaceuticals, 2023
Recent media reports commented about a possible issue of the misuse of antidiabetics related to molecules promoted as a weight-loss treatment in non-obese people.
Stefania Chiappini, Rachel Vickers-Smith, Daniel Harris, G. Duccio Papanti Pelletier, John Martin Corkery, Amira Guirguis, Giovanni Martinotti, Stefano L. Sensi, Fabrizio Schifano   +8 more
doaj   +1 more source

Understanding the Opioid Epidemic through Pharmacovigilance Signals: an Analysis of Pharmacovigilance Datasets collecting Adverse Drug Reactions (ADRs) reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS) over 10 Years

Emerging Trends in Drugs, Addictions, and Health
Introduction: In the past twenty years, the consumption of opioid medications has reached significant proportions, leading to the so-called opioid epidemic, characterized by cyclical waves of heroin use and the non-medical use of pharmaceutical opioids ...
S. Chiappini, R. Vickers-Smith, A. Guirguis, J. Corkery, G. Martinotti, D.R. Harris, F. Schifano   +6 more
doaj   +1 more source

The Bridge Between Classical and “Synthetic”/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective

Frontiers in Psychiatry, 2019
The critical spread and dissemination of novel psychoactive substances (NPS), particularly among the most vulnerable youngsters, may pose a further concern about the psychotic trajectories related to the intake of new synthetic drugs.
Laura Orsolini, Laura Orsolini, Laura Orsolini, Stefania Chiappini, Duccio Papanti, Domenico De Berardis, Domenico De Berardis, Domenico De Berardis, John M. Corkery, Fabrizio Schifano   +9 more
doaj   +1 more source

Case Report: Treatment of Kratom Use Disorder With a Classical Tricyclic Antidepressant

Frontiers in Psychiatry, 2021
Kratom or Mitragyna speciosa (Korth.) is an evergreen tree of the coffee family native to South-East Asia and Australasia. It is used by locals recreationally to induce stimulant and sedative effects and medically to soothe pain and opiate withdrawal ...
Alessandro E. Vento, Alessandro E. Vento, Simone de Persis, Sergio De Filippis, Fabrizio Schifano, Flavia Napoletano, John M. Corkery, Georgios D. Kotzalidis, Georgios D. Kotzalidis   +8 more
doaj   +1 more source